Scholarlink

Background <p>Cryoablation is emerging as a minimally invasive alternative to lumpectomy for select women with early-stage breast cancer. The FROST trial (NCT01992250) was a prospective, phase 2 multicenter study evaluating the outcome of cryoablation in the management of stage I, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative invasive ductal carcinoma.</p> Methods <p>Women 50&#xa0;years old or older with unifocal, ultrasound-visible tumors were stratified by age: stratum 1 (age ≥70&#xa0;years, endocrine therapy only) and stratum 2 (age 50–69 years, endocrine therapy + radiotherapy + optional sentinel node biopsy). Cryoablation was performed using a single cryoprobe under ultrasound guidance. Core biopsy 6&#xa0;months after ablation was performed to confirm complete ablation. Patients were followed with clinical exams and imaging.</p> Results <p>The study included 83 completed cryoablations and follow-up evaluations. The median tumor size was 9&#xa0;mm. More than 85% of the subjects in each group received endocrine therapy (stratum 1 [89%, 43/48], stratum 2 [85.7%, 30/35]) and 74.3% (26/35) of the subjects in stratum 2 received recommended whole-breast radiation. Of the 83 patients, 82 received a post-ablation core biopsy 6 months after cryoablation showing no residual cancer, and 1 patient declined a core biopsy. During a median follow-up period of 6.1 years, the 5-year ipsilateral breast tumor recurrence rate (IBTR) was 3.64% overall (stratum 1, 2.08%; stratum 2, 5.80%). The invasive IBTR-free survival rate was 97.59% overall (stratum 1, 97.92%; stratum 2, 97.14%). No serious adverse events occurred.</p> Conclusions <p>The FROST trial adds to the growing body of literature supporting the efficacy and safety of cryoablation and supports ongoing research on cryoablation as a strategy for de-escalating breast cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月15日

查看全文
  • D. R. Holmes,
  • S. Manoian,
  • R. Layeequr Rahman,
  • R. C. Ward,
  • N. Z. Carp,
  • M. Plaza,
  • K. Kozlowski,
  • S. Abe,
  • L. Bailey,
  • L. Kruper,
  • V. Jones,
  • S. Patterson,
  • J. Tamayo,
  • P. Littrup

摘要

Background

Cryoablation is emerging as a minimally invasive alternative to lumpectomy for select women with early-stage breast cancer. The FROST trial (NCT01992250) was a prospective, phase 2 multicenter study evaluating the outcome of cryoablation in the management of stage I, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative invasive ductal carcinoma.

Methods

Women 50 years old or older with unifocal, ultrasound-visible tumors were stratified by age: stratum 1 (age ≥70 years, endocrine therapy only) and stratum 2 (age 50–69 years, endocrine therapy + radiotherapy + optional sentinel node biopsy). Cryoablation was performed using a single cryoprobe under ultrasound guidance. Core biopsy 6 months after ablation was performed to confirm complete ablation. Patients were followed with clinical exams and imaging.

Results

The study included 83 completed cryoablations and follow-up evaluations. The median tumor size was 9 mm. More than 85% of the subjects in each group received endocrine therapy (stratum 1 [89%, 43/48], stratum 2 [85.7%, 30/35]) and 74.3% (26/35) of the subjects in stratum 2 received recommended whole-breast radiation. Of the 83 patients, 82 received a post-ablation core biopsy 6 months after cryoablation showing no residual cancer, and 1 patient declined a core biopsy. During a median follow-up period of 6.1 years, the 5-year ipsilateral breast tumor recurrence rate (IBTR) was 3.64% overall (stratum 1, 2.08%; stratum 2, 5.80%). The invasive IBTR-free survival rate was 97.59% overall (stratum 1, 97.92%; stratum 2, 97.14%). No serious adverse events occurred.

Conclusions

The FROST trial adds to the growing body of literature supporting the efficacy and safety of cryoablation and supports ongoing research on cryoablation as a strategy for de-escalating breast cancer therapy.